Patient reported outcomes in adolescents with inherited retinal diseases
4 October 2023
| Ian Reekie
|
EYE - Vitreo-Retinal
|
PROM, Patient-reported outcomes, clinical trial, gene therapy, inherited retinal disease, pediatrics, retinal dystrophy
This was a two-centre validation study of two sets of patient reported outcome measures (PROMS) for adolescents (13-17- years-old) with inherited retinal diseases. The measures were the Michigan Retinal Degeneration Questionnaire (MRDQ) and the Michigan Vision-Related Anxiety Questionnaire (MVAQ). Both...
Brolucizumab in age-related macular degeneration, HAWK Study
3 October 2023
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
|
Neovascular age-related macular degeneration, aflibercept, anti-vascular endothelial growth factor therapy, brolucizumab, commercial formulation
The aim of the study was to collect additional data on efficacy and safety of brolucizumab 6mg intended for commercialization in age-related macular degeneration (AMD) (with an increase in pH and decrease in polysorbate concentration). The HAWK Study was a...
Progression of macular atrophy on long-term anti-VEGF therapy for AMD
3 October 2022
| Sofia Rokerya
|
EYE - Vitreo-Retinal
|
Anti-VEGF therapy, Long term, Macular atrophy, neovascular age-related macular degeneration
This retrospective study evaluated the progression of macular atrophy in 53 eyes of 53 patients receiving AntiVEGF Therapy for age-related macular degeneration (nAMD), for at least six years. None of the patients had any macular atrophy (MA) at presentation. MA...
Evaluation of Optive® in ocular discomfort after anti-VEGF intravitreal injection
1 October 2021
| Sofia Rokerya
|
EYE - Vitreo-Retinal
|
Artificial tear, Intravitreal injection therapy, Ocular discomfort, Ocular surface
In this study the authors prospectively evaluated the efficacy of Optive® eye drops after in full, then abbreviation - intravitreal injection (IVT). Patients naïve to IVT were included in the study. No artificial tear treatment was prescribed after the first...
Practice patterns of uveal melanoma management with Iodine-125 brachytherapy
5 August 2020
| Annes Ahmeidat
|
EYE - Pathology, EYE - Oncology
|
Brachytherapy, Treatment practices, Uveal melanoma
With the 2006 Collaborative Ocular Melanoma Study Group (COMS) study demonstrating no difference in survival outcomes for participants randomised to either iodine-125 brachytherapy or enucleation, the majority of primary uveal melanomas in the United States are now treated with brachytherapy....
Episcleral brachytherapy (EB) for retinoblastoma (RB)
5 June 2020
| Jonathan Chan
|
EYE - Pathology, EYE - Oncology
|
episcleral brachytherapy, focal consolidation therapy, ocular survival, recurrence-free survival, retinoblastoma
This retrospective study consisted of 11 eyes treated either with Iodine (I) -125 or Ruthenium (R) -106EB with a mean apical dose of 44Gy. There were five in group B (46%), three in group C (27%) and three in group...
Management of diabetic macular oedema (DMO)
1 February 2018
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
|
Anti-VEGF therapy, Diabetic macular edema, Steroids
The authors present guidelines on current diagnostic and therapeutic procedures in the management of DMO. Fluorescein angiography (FA) and optical coherence tomography (OCT) are recommended before starting treatment to help diagnose and stage DMO, and can be repeated if there...
High dose (2.5mg) bevacizumab for postradiation cystoid macular oedema
1 April 2017
| Yamini Krishna
|
EYE - Pathology, EYE - Oncology
|
Anti-VEGF, Cystoid macular edema, Melanoma, Radiation damage, Radiotherapy, Tumor
The authors present a retrospective, interventional case series investigating the efficacy of high dose (2.5mg/0.1ml) intravitreal bevacizumab in the treatment of persistent postradiation (Iodine-125 plaque brachytherapy for uveal melanoma) cystoid macular oedema (CME). Persistent CME was defined as increased or...
Adjunctive topical 5-FU vs. MMC for surgically excised, localised OSSN
1 October 2014
| Anjali Gupta
|
EYE - Cornea, EYE - General
|
OSSN, chemotherapy, ocular oncology, ocular surface tumours
Ocular surface squamous neoplasia (OSSN) comprises a range of dysplasia including corneal-conjunctival intraepithelial neoplasia and invasive squamous cell carcinoma. The traditional treatment for localised non-invasive OSSN has been surgical excision with or without intraoperative cryotherapy. Postoperative adjunctive topical chemotherapy significantly...
